Randomized Phase 2 Trial of Telitacicept in Patients With IgA Nephropathy With Persistent Proteinuria

INTRODUCTION: To date, no specific therapies have been approved for immunoglobulin A nephropathy (IgAN) treatment. Telitacicept is a fusion protein composed of transmembrane activator and calcium-modulating cyclophilin ligand interactor and fragment crystallizable portion of immunoglobulin G (IgG),...

Descripción completa

Detalles Bibliográficos
Autores principales: Lv, Jicheng, Liu, Lijun, Hao, Chuanming, Li, Guisen, Fu, Ping, Xing, Guangqun, Zheng, Hongguang, Chen, Nan, Wang, Caili, Luo, Ping, Xie, Deqiong, Zuo, Li, Li, Rongshan, Mao, Yonghui, Dong, Shaoshao, Zhang, Pengfei, Zheng, Huixiao, Wang, Yue, Qin, Wei, Wang, Wenxiang, Li, Lin, Jiao, Wenjuan, Fang, Jianmin, Zhang, Hong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Clinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10014376/
https://www.ncbi.nlm.nih.gov/pubmed/36938094
http://dx.doi.org/10.1016/j.ekir.2022.12.014

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10014376/
https://www.ncbi.nlm.nih.gov/pubmed/36938094
http://dx.doi.org/10.1016/j.ekir.2022.12.014

Ejemplares similares